S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.77 (-0.07%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.77 (-0.07%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.77 (-0.07%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.77 (-0.07%)
AAPL   154.98 (-0.63%)
MSFT   257.48 (-0.24%)
META   160.78 (+0.24%)
GOOGL   108.61 (-0.77%)
AMZN   128.61 (-0.67%)
TSLA   285.79 (+0.74%)
NVDA   137.72 (+0.42%)
NIO   17.46 (-0.11%)
BABA   89.07 (-1.69%)
AMD   81.92 (+2.90%)
T   16.84 (-0.18%)
MU   54.54 (-0.84%)
CGC   3.40 (-0.29%)
F   15.18 (-1.62%)
GE   73.24 (-0.46%)
DIS   111.64 (-0.93%)
AMC   8.49 (+1.19%)
PYPL   95.41 (+0.46%)
PFE   46.55 (+0.91%)
NFLX   225.32 (-1.59%)
NASDAQ:RUBY

Rubius Therapeutics - RUBY News Today

$1.22
+0.35 (+40.52%)
(As of 09/8/2022 10:17 AM ET)
Add
Compare
Today's Range
$0.91
▼
$1.22
50-Day Range
$0.65
▼
$0.98
52-Week Range
$0.65
▼
$21.67
Volume
116,913 shs
Average Volume
2.00 million shs
Market Capitalization
$110.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Get Rubius Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

RUBY Media Mentions By Week

RUBY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RUBY
News Sentiment
▼
0.00

0.38
▲
Average
Medical
News Sentiment

RUBY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RUBY Articles
This Week
▼
1

1
▲
RUBY Articles
Average Week



SourceHeadline
msn.com logoPeering Into Rubius Therapeutics's Recent Short Interest
msn.com - September 7 at 10:48 PM
finance.yahoo.com logoRubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - August 11 at 6:19 PM
msn.com logoRubius Therapeutics: Q2 Earnings Insights
msn.com - August 9 at 10:41 AM
tmcnet.com logoRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
tmcnet.com - August 9 at 10:41 AM
finance.yahoo.com logoRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - August 9 at 10:41 AM
finance.yahoo.com logoRubius Therapeutics to Announce Second Quarter 2022 Financial Results
finance.yahoo.com - July 26 at 1:04 PM
finance.yahoo.com logoHotSpot Therapeutics Appoints Jose Carmona to Board of Directors
finance.yahoo.com - July 19 at 7:31 AM
finance.yahoo.com logoRubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
finance.yahoo.com - July 14 at 9:37 AM
finance.yahoo.com logoRubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
finance.yahoo.com - June 22 at 9:14 AM
morningstar.com logoRubius Therapeutics Inc - Stock News
morningstar.com - June 3 at 8:56 AM
finance.yahoo.com logoRubius Therapeutics to Present at the Jefferies Global Healthcare Conference
finance.yahoo.com - June 1 at 4:49 PM
finance.yahoo.com logoRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 26 at 5:42 PM
finance.yahoo.com logoRubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
finance.yahoo.com - May 24 at 10:35 AM
nasdaq.com logoBinance Coin Now Buys You the Greatest Amount of Rubius Therapeutics in the Past Year
nasdaq.com - May 23 at 3:53 PM
seekingalpha.com logoRubius price target lowered at H.C. Wainwright on trial update for cellular therapy
seekingalpha.com - May 11 at 6:24 PM
markets.businessinsider.com logoWhat 6 Analyst Ratings Have To Say About Rubius Therapeutics
markets.businessinsider.com - May 10 at 8:26 PM
finance.yahoo.com logoRubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 10:25 AM
finance.yahoo.com logoRubius Therapeutics to Announce First Quarter 2022 Financial Results
finance.yahoo.com - April 26 at 9:36 AM
seekingalpha.com logoRubius Therapeutics up 34% after insider buy
seekingalpha.com - April 25 at 1:27 PM
markets.businessinsider.com logoGuggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5
markets.businessinsider.com - April 12 at 2:05 AM
seekingalpha.com logoRubius price targets slashed on underwhelming cancer data
seekingalpha.com - April 11 at 4:03 PM
markets.businessinsider.com logoSVB Leerink Maintains Market Perform Rating for Rubius Therapeutics, Lowers Price Target To $3
markets.businessinsider.com - April 11 at 4:03 PM
seekingalpha.com logoRubius Therapeutics tumbles 20% on lowered price target due to disappointing RTX-240 data
seekingalpha.com - April 11 at 4:03 PM
markets.businessinsider.com logoExpert Ratings for Rubius Therapeutics
markets.businessinsider.com - April 11 at 4:03 PM
benzinga.com logoMorgan Stanley Maintains Equal-Weight on Rubius Therapeutics, Lowers Price Target to $4
benzinga.com - April 11 at 10:43 AM
uk.investing.com logoRubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial
uk.investing.com - April 8 at 7:06 PM
tmcnet.com logoRubius Therapeutics Reports Updated Clinical Data at AACR
tmcnet.com - April 8 at 7:06 PM
finance.yahoo.com logoRubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
finance.yahoo.com - April 8 at 7:06 PM
finance.yahoo.com logoRubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
finance.yahoo.com - April 7 at 12:49 PM
nasdaq.com logoNoteworthy Thursday Option Activity: RUBY, MSTR, LMT
nasdaq.com - March 10 at 6:34 PM
seekingalpha.com logoRUBY, MASS and ROVR among after hour movers
seekingalpha.com - March 9 at 10:32 PM
finance.yahoo.com logoRubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
finance.yahoo.com - March 8 at 9:26 PM
benzinga.com logoRecap: Rubius Therapeutics Q4 Earnings
benzinga.com - February 25 at 12:59 PM
seekingalpha.com logoRubius Therapeutics GAAP EPS of -$0.61 misses by $0.02
seekingalpha.com - February 25 at 12:59 PM
finance.yahoo.com logoRubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - February 25 at 12:59 PM
finance.yahoo.com logoRubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
finance.yahoo.com - February 1 at 8:07 AM
seekingalpha.com logoRubius Therapeutics begins dosing in phase 1/2 trial of RTX-224 for solid tumors
seekingalpha.com - January 13 at 1:37 PM
finance.yahoo.com logoRubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
finance.yahoo.com - January 13 at 1:37 PM
finance.yahoo.com logoRubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 10 at 10:18 AM
nasdaq.com logoRubius Therapeutics, Inc. Common Stock (RUBY)
nasdaq.com - January 7 at 10:17 AM
finance.yahoo.com logoRubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 7:55 PM
nasdaq.com logoRubius Therapeutics Inc Shares Close the Day 15.5% Lower - Daily Wrap
nasdaq.com - December 21 at 10:12 AM
finance.yahoo.com logoRubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day
finance.yahoo.com - December 16 at 8:17 AM
finance.yahoo.com logoRubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News
finance.yahoo.com - December 2 at 9:09 AM
finance.yahoo.com logoRubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
finance.yahoo.com - December 1 at 6:05 PM
finance.yahoo.com logoRubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
finance.yahoo.com - November 23 at 10:18 AM
finance.yahoo.com logoRubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
finance.yahoo.com - November 12 at 10:16 AM
finance.yahoo.com logoRubius Therapeutics to Participate in Jefferies London Healthcare Conference
finance.yahoo.com - November 9 at 12:33 PM
finance.yahoo.com logoRubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - November 8 at 9:15 PM
finance.yahoo.com logoIs a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?
finance.yahoo.com - November 5 at 2:31 PM
Get Rubius Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:RUBY) was last updated on 9/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.